We are live on ! Find out more
BRNS

Barinthus Biotherapeutics
BRNS

12 hedge funds and large institutions have $18.4M invested in Barinthus Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.79% less ownership

Funds ownership: 14.06% → 13.28% (-0.79%)

20% less funds holding

Funds holding: 15 → 12 (-3)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

57% less capital invested

Capital invested by funds: $42.4M → $18.4M (-$24M)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
12
Holders Change
-3
Holders Change %
-20%
% of All Funds
0.19%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
2
Increased
2
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$11.1K
2
IIM
Ipswich Investment Management
Massachusetts
+$8.06K
3
JP Morgan Chase
JP Morgan Chase
New York
+$137
4
Citigroup
Citigroup
New York
+$16

Top Sellers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
-$1.54M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$462K
3
ACA
Arena Capital Advisors
California
-$341K
4
EMG
ETF Managers Group
New Jersey
-$108K
5
Millennium Management
Millennium Management
New York
-$18.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$7.87M -$1.54M -190,700 -11%
DF
2
DC Funds
Virginia
$3.34M – – –
LIP
3
Liontrust Investment Partners
United Kingdom
$3.12M – – –
BCM
4
BlueCrest Capital Management
Jersey
$2.82M -$3.23K -400 -0.1%
JHU
5
Johns Hopkins University
Maryland
$561K – – –
Millennium Management
6
Millennium Management
New York
$357K -$18.4K -2,287 -3%
IIM
7
Ipswich Investment Management
Massachusetts
$272K +$8.06K +1,000 +2%
Morgan Stanley
8
Morgan Stanley
New York
$48K -$2.68K -333 -3%
UBS Group
9
UBS Group
Switzerland
$10K +$11.1K +1,383 +241%
MGIM
10
M&G Investment Management
United Kingdom
$5.44K – – –
Hudson Bay Capital Management
11
Hudson Bay Capital Management
Connecticut
– -$462K -41,599 Closed
ACA
12
Arena Capital Advisors
California
– -$341K -30,698 Closed
EMG
13
ETF Managers Group
New Jersey
– -$108K -10,087 Closed
Wells Fargo
14
Wells Fargo
California
– -$6K -500 Closed
Citigroup
15
Citigroup
New York
– +$16 +2 New
JP Morgan Chase
16
JP Morgan Chase
New York
– +$137 +17 New

BRNS Hedge Fund Activity: Q1 2022 in Review

12 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q1 2022, worth a combined $18.4M — down 57% from $42.4M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of BRNS and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $11.1K. The largest seller was Alphabet Inc, cutting an estimated $1.54M.

  • 12 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q1 2022, down from 15 in Q4 2021.
  • Funds reported $18.4M of Barinthus Biotherapeutics stock for Q1 2022, down 57% quarter-over-quarter.
  • 2 funds opened new Barinthus Biotherapeutics positions in Q1 2022 and 5 closed out, a net change of -3 holders.
  • The largest Barinthus Biotherapeutics buyer in Q1 2022 was UBS Group, an estimated $11.1K added.
  • The largest Barinthus Biotherapeutics seller in Q1 2022 was Alphabet Inc, an estimated $1.54M sold.

Based on aggregated 13F filings for Q1 2022.